Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers

Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxici...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Sakamuri, Divya, Glitza, Isabella C., Betancourt Cuellar, Sonia L., Subbiah, Vivek, Fu, Siqing, Tsimberidou, Apostolia M., Wheler, Jennifer J., Hong, David S., Naing, Aung, Falchook, Gerald S., Fanale, Michelle A., Cabanillas, Maria E., Janku, Filip
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935561/
https://ncbi.nlm.nih.gov/pubmed/29237802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0673
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados